ZW25 (Zanidatamab)
ZWI-ZW25-201
Phase 2 small_molecule completed
Quick answer
ZW25 (Zanidatamab) for HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed